Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,026 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,026 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the sale, the insider now directly owns 144,782 shares of the company’s stock, valued at approximately $21,143,963.28. This trade represents a 0.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Stock Performance

Shares of NTRA opened at $150.87 on Thursday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.40 billion, a price-to-earnings ratio of -85.72 and a beta of 1.80. The stock has a 50 day moving average of $162.25 and a 200 day moving average of $149.27. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently modified their holdings of the business. Cerity Partners LLC increased its position in shares of Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after acquiring an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Natera during the third quarter valued at $385,000. Everence Capital Management Inc. bought a new position in Natera during the fourth quarter valued at $573,000. Alpha DNA Investment Management LLC bought a new position in Natera during the third quarter valued at $505,000. Finally, First Turn Management LLC bought a new position in Natera during the third quarter valued at $19,760,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NTRA shares. The Goldman Sachs Group raised their target price on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday. Guggenheim lifted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Piper Sandler lifted their target price on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Natera in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.